Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of XXB750 in resistant hypertension
NL-OMON53418Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of xxb750 in resistant hypertension (RH) (5 arms), sponsored by Novartis. Started Mar 2023; status: completed.
02
Drugs
xxb750
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on NL-OMON53418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53418.